Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports Article Swipe

View

Pugazhenthan Thangaraju , Sajıtha Venkatesan , Meenalotchini Prakash Gurunthalingam , Shoban Babu , T Tamilselvan ·

YOU? · · 2021 · Open Access · · DOI: https://doi.org/10.6084/m9.figshare.14277102

INTRODUCTION: Thalidomide is an anti- tumor necrosis factor alpha (TNF-a) drug used mainly in the management of moderate to severe form of Erythema Nodosum Leprosum (ENL). Because of its teratogenic potential it has to be used under proper supervision. Our critical analysis tries to look into the rationale with which it has been used by means of case reports on lepra reaction. METHODS: We looked for the case reports between December 2005 to June 2019 in databases like Pubmed, Embase and other relevant resources. We used search words like “erythema nodosum leprosum(ENL)”, “thalidomide”, “case report” in different combinations to get relevant reports that focus on thalidomide usage atleast once at any time point during management. The information extracted were indication of thalidomide use, dose, response, outcome, complication if any, along with all the demographic details and geographical distribution. RESULTS: We found 41 case reports eligible for analysis.The information was critically evaluated. From the analysis it was found that 7 of the case report mentioned the exact indication, 4 case report showed irrational use of thalidomide in the case of neuritis without use of steroids, 7 showed proper use of Clofazimine prior to thalidomide initiation, 26 case report showed case report of rationale dose range and in 4 case reports clofazimine was used prior to thalidomide along with the rational dose of thalidomide. CONCLUSIONS: This analysis helps to guide the rationale use of thalidomide focussing on few important points that anyone should keep in mind while managing a case of ENL.

Related Topics

Concepts

Thalidomide Dermatology Erythema nodosum Leprosy Medicine Internal medicine Multiple myeloma Disease

Metadata

Type: dataset
Language: en
Landing Page: https://doi.org/10.6084/m9.figshare.14277102
OA Status: gold
Related Works: 10
OpenAlex ID: https://openalex.org/W4394224793

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4394224793

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.6084/m9.figshare.14277102

Digital Object Identifier
Title: Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports

Work title
Type: dataset

OpenAlex work type
Language: en

Primary language
Publication year: 2021

Year of publication
Publication date: 2021-01-01

Full publication date if available
Authors: Pugazhenthan Thangaraju, Sajıtha Venkatesan, Meenalotchini Prakash Gurunthalingam, Shoban Babu, T Tamilselvan

List of authors in order
Landing page: https://doi.org/10.6084/m9.figshare.14277102

Publisher landing page
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://doi.org/10.6084/m9.figshare.14277102

Direct OA link when available
Concepts: Thalidomide, Dermatology, Erythema nodosum, Leprosy, Medicine, Internal medicine, Multiple myeloma, Disease

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4394224793
doi	https://doi.org/10.6084/m9.figshare.14277102
ids.doi	https://doi.org/10.6084/m9.figshare.14277102
ids.openalex	https://openalex.org/W4394224793
fwci
type	dataset
title	Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T12107
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.9998000264167786
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2725
topics[0].subfield.display_name	Infectious Diseases
topics[0].display_name	Leprosy Research and Treatment
topics[1].id	https://openalex.org/T13374
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.9797999858856201
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2711
topics[1].subfield.display_name	Emergency Medicine
topics[1].display_name	Hematological disorders and diagnostics
topics[2].id	https://openalex.org/T10649
topics[2].field.id	https://openalex.org/fields/27
topics[2].field.display_name	Medicine
topics[2].score	0.9739000201225281
topics[2].domain.id	https://openalex.org/domains/4
topics[2].domain.display_name	Health Sciences
topics[2].subfield.id	https://openalex.org/subfields/2720
topics[2].subfield.display_name	Hematology
topics[2].display_name	Multiple Myeloma Research and Treatments
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C2779609412
concepts[0].level	3
concepts[0].score	0.8071340322494507
concepts[0].wikidata	https://www.wikidata.org/wiki/Q203174
concepts[0].display_name	Thalidomide
concepts[1].id	https://openalex.org/C16005928
concepts[1].level	1
concepts[1].score	0.6484335064888
concepts[1].wikidata	https://www.wikidata.org/wiki/Q171171
concepts[1].display_name	Dermatology
concepts[2].id	https://openalex.org/C2777410594
concepts[2].level	3
concepts[2].score	0.5843886137008667
concepts[2].wikidata	https://www.wikidata.org/wiki/Q1363738
concepts[2].display_name	Erythema nodosum
concepts[3].id	https://openalex.org/C2780695269
concepts[3].level	2
concepts[3].score	0.45930230617523193
concepts[3].wikidata	https://www.wikidata.org/wiki/Q36956
concepts[3].display_name	Leprosy
concepts[4].id	https://openalex.org/C71924100
concepts[4].level	0
concepts[4].score	0.42565420269966125
concepts[4].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[4].display_name	Medicine
concepts[5].id	https://openalex.org/C126322002
concepts[5].level	1
concepts[5].score	0.13551971316337585
concepts[5].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[5].display_name	Internal medicine
concepts[6].id	https://openalex.org/C2776364478
concepts[6].level	2
concepts[6].score	0.0
concepts[6].wikidata	https://www.wikidata.org/wiki/Q467635
concepts[6].display_name	Multiple myeloma
concepts[7].id	https://openalex.org/C2779134260
concepts[7].level	2
concepts[7].score	0.0
concepts[7].wikidata	https://www.wikidata.org/wiki/Q12136
concepts[7].display_name	Disease
keywords[0].id	https://openalex.org/keywords/thalidomide
keywords[0].score	0.8071340322494507
keywords[0].display_name	Thalidomide
keywords[1].id	https://openalex.org/keywords/dermatology
keywords[1].score	0.6484335064888
keywords[1].display_name	Dermatology
keywords[2].id	https://openalex.org/keywords/erythema-nodosum
keywords[2].score	0.5843886137008667
keywords[2].display_name	Erythema nodosum
keywords[3].id	https://openalex.org/keywords/leprosy
keywords[3].score	0.45930230617523193
keywords[3].display_name	Leprosy
keywords[4].id	https://openalex.org/keywords/medicine
keywords[4].score	0.42565420269966125
keywords[4].display_name	Medicine
keywords[5].id	https://openalex.org/keywords/internal-medicine
keywords[5].score	0.13551971316337585
keywords[5].display_name	Internal medicine
language	en
locations[0].id	doi:10.6084/m9.figshare.14277102
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url
locations[0].version
locations[0].raw_type	dataset
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	False
locations[0].is_published
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.6084/m9.figshare.14277102
indexed_in	datacite
authorships[0].author.id	https://openalex.org/A5085253964
authorships[0].author.orcid
authorships[0].author.display_name	Pugazhenthan Thangaraju
authorships[0].author_position	first
authorships[0].raw_author_name	Pugazhenthan Thangaraju
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5026841501
authorships[1].author.orcid
authorships[1].author.display_name	Sajıtha Venkatesan
authorships[1].author_position	middle
authorships[1].raw_author_name	Sajitha Venkatesan
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5088326769
authorships[2].author.orcid
authorships[2].author.display_name	Meenalotchini Prakash Gurunthalingam
authorships[2].author_position	middle
authorships[2].raw_author_name	Meenalotchini Gurunthalingam
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5108123769
authorships[3].author.orcid
authorships[3].author.display_name	Shoban Babu
authorships[3].author_position	middle
authorships[3].raw_author_name	Shoban Babu
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5002275215
authorships[4].author.orcid
authorships[4].author.display_name	T Tamilselvan
authorships[4].author_position	last
authorships[4].raw_author_name	Tamilselvan T
authorships[4].is_corresponding	False
has_content.pdf	False
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://doi.org/10.6084/m9.figshare.14277102
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T06:51:31.235846
primary_topic.id	https://openalex.org/T12107
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.9998000264167786
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2725
primary_topic.subfield.display_name	Infectious Diseases
primary_topic.display_name	Leprosy Research and Treatment
related_works	https://openalex.org/W2748952813, https://openalex.org/W3031052312, https://openalex.org/W4389568370, https://openalex.org/W3032375762, https://openalex.org/W1995515455, https://openalex.org/W2080531066, https://openalex.org/W3108674512, https://openalex.org/W1506200166, https://openalex.org/W1489783725, https://openalex.org/W2247197151
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.6084/m9.figshare.14277102
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url
best_oa_location.version
best_oa_location.raw_type	dataset
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	False
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.6084/m9.figshare.14277102
primary_location.id	doi:10.6084/m9.figshare.14277102
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url
primary_location.version
primary_location.raw_type	dataset
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	False
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.6084/m9.figshare.14277102
publication_date	2021-01-01
publication_year	2021
referenced_works_count	0
abstract_inverted_index.4	168, 207
abstract_inverted_index.7	159, 185
abstract_inverted_index.a	247
abstract_inverted_index.26	195
abstract_inverted_index.41	142
abstract_inverted_index.We	64, 85, 140
abstract_inverted_index.an	4
abstract_inverted_index.at	110
abstract_inverted_index.be	35
abstract_inverted_index.by	55
abstract_inverted_index.if	128
abstract_inverted_index.in	14, 76, 96, 176, 206, 243
abstract_inverted_index.is	3
abstract_inverted_index.it	32, 51, 155
abstract_inverted_index.of	17, 22, 28, 57, 121, 160, 174, 179, 183, 189, 201, 221, 232, 249
abstract_inverted_index.on	60, 105, 235
abstract_inverted_index.to	19, 34, 44, 73, 99, 192, 214, 227
abstract_inverted_index.Our	40
abstract_inverted_index.The	116
abstract_inverted_index.all	132
abstract_inverted_index.and	81, 136, 205
abstract_inverted_index.any	111
abstract_inverted_index.few	236
abstract_inverted_index.for	66, 146
abstract_inverted_index.get	100
abstract_inverted_index.has	33, 52
abstract_inverted_index.its	29
abstract_inverted_index.the	15, 47, 67, 133, 153, 161, 165, 177, 218, 229
abstract_inverted_index.use	173, 182, 188, 231
abstract_inverted_index.was	149, 156, 211
abstract_inverted_index.2005	72
abstract_inverted_index.2019	75
abstract_inverted_index.ENL.	250
abstract_inverted_index.From	152
abstract_inverted_index.June	74
abstract_inverted_index.This	224
abstract_inverted_index.any,	129
abstract_inverted_index.been	53
abstract_inverted_index.case	58, 68, 143, 162, 169, 178, 196, 199, 208, 248
abstract_inverted_index.dose	203, 220
abstract_inverted_index.drug	11
abstract_inverted_index.form	21
abstract_inverted_index.into	46
abstract_inverted_index.keep	242
abstract_inverted_index.like	78, 89
abstract_inverted_index.look	45
abstract_inverted_index.mind	244
abstract_inverted_index.once	109
abstract_inverted_index.that	103, 158, 239
abstract_inverted_index.time	112
abstract_inverted_index.use,	123
abstract_inverted_index.used	12, 36, 54, 86, 212
abstract_inverted_index.were	119
abstract_inverted_index.with	49, 131, 217
abstract_inverted_index.along	130, 216
abstract_inverted_index.alpha	9
abstract_inverted_index.anti-	5
abstract_inverted_index.dose,	124
abstract_inverted_index.exact	166
abstract_inverted_index.focus	104
abstract_inverted_index.found	141, 157
abstract_inverted_index.guide	228
abstract_inverted_index.helps	226
abstract_inverted_index.lepra	61
abstract_inverted_index.means	56
abstract_inverted_index.other	82
abstract_inverted_index.point	113
abstract_inverted_index.prior	191, 213
abstract_inverted_index.range	204
abstract_inverted_index.tries	43
abstract_inverted_index.tumor	6
abstract_inverted_index.under	37
abstract_inverted_index.usage	107
abstract_inverted_index.which	50
abstract_inverted_index.while	245
abstract_inverted_index.words	88
abstract_inverted_index.(ENL).	26
abstract_inverted_index.Embase	80
abstract_inverted_index.anyone	240
abstract_inverted_index.during	114
abstract_inverted_index.factor	8
abstract_inverted_index.looked	65
abstract_inverted_index.mainly	13
abstract_inverted_index.points	238
abstract_inverted_index.proper	38, 187
abstract_inverted_index.report	163, 170, 197, 200
abstract_inverted_index.search	87
abstract_inverted_index.severe	20
abstract_inverted_index.should	241
abstract_inverted_index.showed	171, 186, 198
abstract_inverted_index.(TNF-a)	10
abstract_inverted_index.Because	27
abstract_inverted_index.Nodosum	24
abstract_inverted_index.Pubmed,	79
abstract_inverted_index.atleast	108
abstract_inverted_index.between	70
abstract_inverted_index.details	135
abstract_inverted_index.nodosum	91
abstract_inverted_index.reports	59, 69, 102, 144, 209
abstract_inverted_index.without	181
abstract_inverted_index.“case	94
abstract_inverted_index.Abstract	0
abstract_inverted_index.December	71
abstract_inverted_index.Erythema	23
abstract_inverted_index.Leprosum	25
abstract_inverted_index.METHODS:	63
abstract_inverted_index.RESULTS:	139
abstract_inverted_index.analysis	42, 154, 225
abstract_inverted_index.critical	41
abstract_inverted_index.eligible	145
abstract_inverted_index.managing	246
abstract_inverted_index.moderate	18
abstract_inverted_index.necrosis	7
abstract_inverted_index.neuritis	180
abstract_inverted_index.outcome,	126
abstract_inverted_index.rational	219
abstract_inverted_index.relevant	83, 101
abstract_inverted_index.databases	77
abstract_inverted_index.different	97
abstract_inverted_index.extracted	118
abstract_inverted_index.focussing	234
abstract_inverted_index.important	237
abstract_inverted_index.mentioned	164
abstract_inverted_index.potential	31
abstract_inverted_index.rationale	48, 202, 230
abstract_inverted_index.reaction.	62
abstract_inverted_index.report”	95
abstract_inverted_index.response,	125
abstract_inverted_index.steroids,	184
abstract_inverted_index.critically	150
abstract_inverted_index.evaluated.	151
abstract_inverted_index.indication	120
abstract_inverted_index.irrational	172
abstract_inverted_index.management	16
abstract_inverted_index.resources.	84
abstract_inverted_index.Clofazimine	190
abstract_inverted_index.Thalidomide	2
abstract_inverted_index.clofazimine	210
abstract_inverted_index.demographic	134
abstract_inverted_index.indication,	167
abstract_inverted_index.information	117, 148
abstract_inverted_index.initiation,	194
abstract_inverted_index.management.	115
abstract_inverted_index.teratogenic	30
abstract_inverted_index.thalidomide	106, 122, 175, 193, 215, 233
abstract_inverted_index.“erythema	90
abstract_inverted_index.CONCLUSIONS:	223
abstract_inverted_index.analysis.The	147
abstract_inverted_index.combinations	98
abstract_inverted_index.complication	127
abstract_inverted_index.geographical	137
abstract_inverted_index.supervision.	39
abstract_inverted_index.thalidomide.	222
abstract_inverted_index.INTRODUCTION:	1
abstract_inverted_index.distribution.	138
abstract_inverted_index.leprosum(ENL)”,	92
abstract_inverted_index.“thalidomide”,	93
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	5
citation_normalized_percentile